|
|
|
| Clinical effect of Ligustrazine and Glucagon-like Peptide 1 Receptor Agonist in the treatment of chronic complications of type 2 diabetes |
| CHEN Zai-ming |
| Department of Endocrinology, Puning Overseas Chinese Hospital, Guangdong Province, Puning 515300, China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Ligustrazine and Glucagon-like Peptide 1 (GLP-1) Receptor Agonist in the treatment of chronic complications of type 2 diabetes (T2DM). Methods From January to June 2019, 90 cases of chronic complications of T2DM treated in our hospital were selected and were divided into three groups：Ligustrazine group (n=30), the agonist group (n=30) and the combined group (n=30) according to the random number table method. All three groups were treated with oral treatment, diet guidance and health education to complete the disease treatment. The Ligustrazin group was given Ligustrazin intravenous drip; the agonist group was treated with GLP-1 Receptor Agonist; the combined group was treated with Ligustrazin and GLP-1 Receptor Agonist. After treatment, the clinical efficacy, blood glucose, erythrocyte aldose reductase (AR) activity and glycosylated hemoglobin (HbA1c) were compared among the three groups. Results The total effective rate of the combined group was 100.0%, which was higher than those of the Ligustrazin group (83.3%) and the agonist group (86.7%) (P＜0.05), but there was no significant difference between the Ligustrazin group and the agonist group (P＞0.05). The activity of fasting blood sugar (FPG), 2 hours postprandial blood glucose （2 hPG）, AR and HbA1c in the combined group were lower than those in the Ligustrazine group and the agonist group, and the differences were statistically significant (P＜0.05), but there was no significant difference between the Ligustrazin group and the agonist group (P＞0.05). Conclusion On the basis of routine active intervention, the combination of Ligustrazine and GLP-1 Receptor agonist in patients with chronic complications of T2DM has more positive and obvious effect, which is of great value in terms of short-term and long-term curative effects.
|
|
|
|
|
|
| [1] |
刘智健，代成刚．GLP-1 类似物与DPP-4 抑制剂对肥胖2 型糖尿病患者疗效观察[J].吉林医学，2016，37（2）：327-329．
|
| [2] |
李玲，于文君，严妍，等.GLP-1 受体激动剂调节2 型糖尿病糖脂代谢研究进展[J].中国医院药学杂志，2017，10：22-23.
|
| [3] |
常宁.川芎嗪注射剂治疗冠心病合并糖尿病的效果分析[J].齐齐哈尔医学院学报，2017，38（13）：1560-1561.
|
| [4] |
曾玉，王华，赵新兰，等.胰高血糖素样肽-1 受体激动剂治疗糖尿病慢性并发症的研究进展[J].中国老年学杂志，2018，38（18）：4566-4568.
|
| [5] |
范德宇，姜默琳，冒慧敏，等.胰高血糖素样肽-1 在中医振腹疗法治疗2 型糖尿病中的机制探讨[J].世界中医药，2014，9（12）：1640-1641.
|
| [6] |
钟娟，覃薇，青姚，等.川芎嗪对糖尿病肾病大鼠血液流变学、醛糖还原酶及肾功能的影响[J].中成药，2017，39（11）：2231-2235.
|
| [7] |
陈英，詹晓蓉，殷微微，等.2 型糖尿病患者早期使用胰高血糖素样受体激动剂[J]．现代生物医学进展，2015，15（11）：2195-2196.
|
| [8] |
王英俊，罗科学.胰高血糖素样肽-1 受体激动剂治疗2 型糖尿病的临床疗效及安全性观察[J].中国现代医生，2018，56（36）：22-24，28.
|
| [9] |
汤娜.丹参川芎嗪注射液联合福辛普利对糖尿病肾病蛋白尿患者的临床疗效[J].中成药，2019，41（3）：559-562.
|
| [10] |
傅永锦，夏雪怡，张小牧，等.川芎嗪对糖尿病肾病大鼠下调HMGB1 表达及降低RAGEs 作用[J].中国临床药理学与治疗学，2017，22（8）：846-851.
|
| [11] |
吐拉古丽·玉素甫，热孜万古丽·买买提.川芎嗪治疗糖尿病慢性并发症的临床效果探析[J].世界最新医学信息文摘，2018，18（84）：157.
|
| [12] |
宋春宇，王中京，毛红，等.丹参川芎嗪注射液对糖尿病肾病大鼠微循环障碍及肾功能的影响[J].中国老年学杂志，2017，37（10）：2396-2398.
|
| [13] |
齐鲁钰，阳柳雪.胰高血糖素样肽-1 受体激动剂治疗2型糖尿病的临床疗效及安全性研究进展[J].临床合理用药杂志，2018，11（6）：168-170.
|
| [14] |
刘心苑，刘尚全.胰高血糖素样肽1 受体激动剂治疗2型糖尿病的临床进展[J].临 床荟萃，2018，33（5）：446-453.
|
| [15] |
周玥，何梅，杨明，等.GLP-1 受体激动剂与DPP-4 抑制剂比较治疗2 型糖尿病效果的系统评价[J].中国循证医学杂志，2014，14（12）：1459-1466.
|
|
|
|
